UroGen's ZUSDURI Demonstrates Durable Complete Responses Across All Bladder Cancer Risk Groups
URGN has more than doubled off its 52-week low of $3.42.
Summary
UroGen Pharma announced new post-hoc analyses from its Phase 3 ENVISION trial for ZUSDURI, demonstrating durable complete response (CR) rates across all European Organization for Research and Treatment of Cancer (EORTC) recurrence score groups in patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The data showed CR rates at three months of 83.9%, 81.2%, and 60.0% for low, intermediate, and high EORTC recurrence scores, respectively, with most responders remaining recurrence-free at 24 months. This robust efficacy, even in higher-risk patients, significantly strengthens ZUSDURI's clinical profile and commercial potential. The findings reinforce the drug's value as a non-surgical treatment option and will be presented at ASCO-GU 2026, potentially boosting clinician awareness and adoption.
At the time of this announcement, URGN was trading at $20.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $991.4M. The 52-week trading range was $3.42 to $30.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.